OncoMatch/Cervical Cancer/PD-L1 (CD274)
Cervical CancerPD-L1 (CD274) Clinical Trials
PD-L1 CPS ≥1 is required for pembrolizumab eligibility as first-line treatment in persistent, recurrent, or metastatic cervical cancer in combination with chemotherapy (with or without bevacizumab) per KEYNOTE-826. PD-L1 CPS ≥1 is also the threshold for second-line pembrolizumab monotherapy per KEYNOTE-158. Trials investigate novel checkpoint combinations, anti-VEGF/IO regimens, and neoadjuvant immunotherapy in locally advanced cervical cancer.
Top recruiting PD-L1 (CD274) Cervical Cancer trials
Ranked by phase and US site count. See all 14 trials matched to your profile →
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Merck Sharp & Dohme LLC
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Bio-Thera Solutions
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Tongji Hospital
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
AstraZeneca
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Precigen, Inc